|
|
| (18 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | ACE2; any specific functions of spike protein; | | ACE2; any specific functions of spike protein; |
| − | see also '''[[RSP - On RAS drugs]]'''
| + | {{up|PHA antivirals by mechanism}} |
| | + | {{up|PHA pharmacophore by screened target}} |
| | | | |
| | + | {{qt|PHA ACE2 Structure spike-ace2}} |
| | + | {{qt|PHA ACE2 in target tissues}} |
| | + | {{qt|PHA ACE2 regulation of ACE2}} |
| | + | {{qt|PHA ACE2 drug design}} spike RBD |
| | + | {{qt|PHA SCR spike protein general aspects}} spike any target |
| | + | {{qt|PHA ACE2 amplification}} |
| | + | {{qt|PHA ACE2 soluble ace2}} |
| | + | {{qt|PHA Angiotensin(1-7)}} |
| | + | {{qt|PHA Angiotensin II}} |
| | + | {{qt|RSP - On RAS drugs}} |
| | + | {{qt|MOD ACE2 transgenic mice}} |
| | + | {{qt|MOD Zebrafish}} |
| | + | {{qt|PHA ACE2 ace2 species specificity clade specificity}} |
| | | | |
| − | '''regulation of ace2'''
| |
| − | {{tp|p=32291076|t=ä. EZH2-mediated H3K27me3 inhibits ACE2 expression |pdf=|usr=}}
| |
| − | {{tp|p=32133153|t=2020. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations |pdf=|usr=}}
| |
| − | {{tp|p=32372801|t=2020. (ACE2) Does a cell protein explain covid-19 severity?|pdf=|usr=}}
| |
| − | {{tp|p=32302706|t=2020. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor |pdf=|usr=}}
| |
| | | | |
| − | '''ace2 species specificity clade specificity'''
| + | {{ttp|p=32449939|t=2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection.|pdf=|usr=007}} |
| − | {{tp|p=32092392|t=2020. Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV |pdf=|usr=}} | + | {{tp|p=32582574|t=2020. ACE2, Much More Than Just a Receptor for SARS-COV-2.|pdf=|usr=011}} |
| − | {{tp|p=32199943|t=ä. Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2 |pdf=|usr=}}
| + | {{tp|p=32738617|t=2020. ACE2 Co-evolutionary Pattern Suggests Targets for Pharmaceutical Intervention in the COVID-19 Pandemic.|pdf=|usr=018}} |
| − | {{tp|p=32100877|t=ä. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS?CoV?2 |pdf=|usr=}}
| + | {{tp|p=32602627|t=2020. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.|pdf=|usr=011}} |
| − | {{tp|p=32249956|t=ä. Structural variations in human ACE2 may influence its binding with SARS?CoV?2 spike protein |pdf=|usr=}}
| + | {{tp|p=32585135|t=2020. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.|pdf=|usr=010}} |
| − | {{tp|p=32374452|t=2020. SARS-CoV-2: Structural diversity, phylogeny, and potential animal host identification of spike glycoprotein |pdf=|usr=}}
| + | {{tp|p=32747721|t=2020. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.|pdf=|usr=018}} |
| − | {{tp|p=32239522|t=ä. SARS?CoV?2 spike protein favors ACE2 from Bovidae and Cricetidae |pdf=|usr=}}
| + | {{tp|p=32913581|t=2020. Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike.|pdf=|usr=019}} |
| − | | + | |
| − | '''any receptors in target tissues'''
| + | |
| − | {{tp|p=32199615|t=ä. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | '''ACE2 expression in target tissues'''
| + | |
| − | {{tp|p=32279908|t=ä. Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection?|pdf=|usr=}}
| + | |
| − | {{tp|p=32251718|t=2020. ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32227090|t=ä. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32364961|t=2020. Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?|pdf=|usr=}} | + | |
| − | | + | |
| − | | + | |
| − | '''Structure spike/ace2'''
| + | |
| − | | + | |
| − | {{tp|p=32057769|t=2020. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade |pdf=|usr=}}
| + | |
| − | {{tp|p=32155444|t=ä. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein |pdf=|usr=}}
| + | |
| − | {{tp|p=32178593|t=2020. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26 |pdf=|usr=}}
| + | |
| − | {{tp|p=32320687|t=ä. Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop |pdf=|usr=}}
| + | |
| − | {{tp|p=32009228|t=2020. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission |pdf=|usr=}}
| + | |
| − | {{tp|p=32075877|t=2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation |pdf=|usr=}}
| + | |
| − | {{tp|p=32081428|t=2020. Structure analysis of the receptor binding of 2019-nCoV |pdf=|usr=}}
| + | |
| − | {{tp|p=32142651|t=2020. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor |pdf=|usr=}}
| + | |
| − | {{tp|p=32203189|t=ä. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine |pdf=|usr=}}
| + | |
| − | {{tp|p=32275855|t=ä. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32201080|t=ä. Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32210742|t=2020. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis |pdf=|usr=}} | + | |
| − | {{tp|p=32327200|t=ä. Covid-19 and the angiotensin-converting enzyme (ACE2): Areas for research |pdf=|usr=}}
| + | |
| − | {{ttp|p=32274964|t=2020. A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin |pdf=|usr=}}
| + | |
| − | {{tp|p=31996437|t=2020. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus |pdf=|usr=}}
| + | |
| − | {{ttp|p=32362314|t=ä. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells |pdf=|usr=}}
| + | |
| − | {{tp|p=32221306|t=2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV |pdf=|usr=}}
| + | |
| − | {{ttp|p=32150576|t=2020. Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry |pdf=|usr=}}
| + | |
| − | {{tp|p=32245784|t=2020. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV |pdf=|usr=}}
| + | |
| − | {{ttp|p=32366695|t=ä. Site-specific glycan analysis of the SARS-CoV-2 spike |pdf=|usr=}}
| + | |
| − | {{tp|p=32132184|t=2020. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32198713|t=ä. A Unique Protease Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia Coronavirus (2019-nCoV) Potentially Related to Viral Transmissibility |pdf=|usr=}}
| + | |
| − | {{tp|p=32365751|t=2020. The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor |pdf=|usr=}}
| + | |
| − | {{tp|p=32378705|t=2020. A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity |pdf=|usr=}}
| + | |
| − | {{tp|p=32132669|t=2020. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV |pdf=|usr=}}
| + | |
| − | {{tp|p=32338224|t=2020. Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target - A Perspective |pdf=|usr=}} | + | |
| − | {{tp|p=32363391|t=ä. Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{ttp|p=32374903|t=2020. SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate |pdf=|usr=}}
| + | |
| − | {{tp|p=32376714|t=2020. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein |pdf=|usr=}}
| + | |
| − | {{tp|p=32225176|t=2020. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor |pdf=|usr=}}
| + | |
| − | {{tp|p=32225175|t=2020. Structural basis of receptor recognition by SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32329276|t=2020. Spike protein in the detection and treatment of novel coronavirus |pdf=|usr=}}
| + | |
| − | {{tp|p=C7190498|t=ä. The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650 |pdf=|usr=}}
| + | |
| − | {{tp|p=32125455|t=ä. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target |pdf=|usr=}}
| + | |
| − | {{tp|p=32369402|t=2020. ANNALS EXPRESS: Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: a closer look at angiotensin-converting enzyme 2 (ACE2) |pdf=|usr=}}
| + | |
| − | {{tp|p=32354022|t=2020. ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel?|pdf=|usr=}}
| + | |
| − | {{tp|p=32306452|t=2020. Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword?|pdf=|usr=}}
| + | |
| − | | + | |
| − | '''Drug design'''
| + | |
| − | | + | |
| − | {{ttp|p=C7151553|t=2020. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles? heel conserved region to minimize probability of escape mutations and drug resistance |pdf=|usr=}}
| + | |
| − | {{tp|p=32286790|t=ä. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2 |pdf=|usr=}} | + | |
| − | {{tp|p=32333836|t=ä. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32231345|t=2020. Inhibition of SARS-CoV-2 infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion |pdf=|usr=}}
| + | |
| − | {{tp|p=32354636|t=ä. Blockade of SARS-CoV-2 infection by recombinant soluble ACE2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32332922|t=ä. SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32294562|t=ä. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease |pdf=|usr=}} | + | |
| − | {{tp|p=32359080|t=2020. Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?|pdf=|usr=}}
| + | |
| − | {{tp|p=32167153|t=2020. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?|pdf=|usr=}}
| + | |
| − | {{tp|p=32373991|t=2020. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking |pdf=|usr=}}
| + | |
| − | {{tp|p=32232976|t=2020. CD-sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32362217|t=2020. In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria |pdf=|usr=}} | + | |
| − | {{tp|p=32345124|t=2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets |pdf=|usr=}}
| + | |
| − | {{tp|p=32379346|t=2020. ACE2 Activators for the Treatment of Covid 19 Patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32332765|t=2020. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig |pdf=|usr=}}
| + | |
| − | {{tp|p=32376627|t=2020. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity |pdf=|usr=}}
| + | |
| − | {{tp|p=32380200|t=ä. In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{ttp|p=C7197610|t=ä. Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy |pdf=|usr=}}
| + | |
| − | {{ttp|p=32231345|t=ä. Inhibition of SARS-CoV-2 infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion |pdf=|usr=}}''Here we generated a series of lipopeptides derived from EK1 and found that EK1C4 was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection''
| + | |
| − | {{tp|p=32336762|t=2012. Design of Angiotensin?converting Enzyme 2 (ACE2) Inhibitors by Virtual Lead Optimization and Screening |pdf=|usr=}}
| + | |
| − | {{tp|p=32380200|t=2020. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32065055|t=2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody |pdf=|usr=}}
| + | |
| − | {{tp|p=32285293|t=ä. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV |pdf=|usr=}}
| + | |
| − | {{tp|p=32313207|t=ä. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor |pdf=|usr=}}
| + | |
| − | {{tp|p=32451080|t=ä. A possible strategy to fight COVID-19: Interfering with spike glycoprotein trimerization |pdf=|usr=}}
| + | |
